Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $74.64 million. The enterprise value is $58.78 million.
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 42.65 million shares outstanding. The number of shares has increased by 42.24% in one year.
| Current Share Class | 42.65M |
| Shares Outstanding | 42.65M |
| Shares Change (YoY) | +42.24% |
| Shares Change (QoQ) | +11.66% |
| Owned by Insiders (%) | 2.36% |
| Owned by Institutions (%) | 19.65% |
| Float | 41.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.31 |
| P/TBV Ratio | 5.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.05.
| Current Ratio | 4.69 |
| Quick Ratio | 4.51 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -214.69% and return on invested capital (ROIC) is -116.96%.
| Return on Equity (ROE) | -214.69% |
| Return on Assets (ROA) | -81.15% |
| Return on Invested Capital (ROIC) | -116.96% |
| Return on Capital Employed (ROCE) | -132.72% |
| Weighted Average Cost of Capital (WACC) | 5.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.01M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $943,675 in taxes.
| Income Tax | 943,675 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.26% in the last 52 weeks. The beta is 0.16, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -10.26% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 2.20 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 581,259 |
Short Selling Information
The latest short interest is 3.20 million, so 7.50% of the outstanding shares have been sold short.
| Short Interest | 3.20M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 7.50% |
| Short % of Float | 7.68% |
| Short Ratio (days to cover) | 5.13 |
Income Statement
| Revenue | n/a |
| Gross Profit | -10.59M |
| Operating Income | -19.71M |
| Pretax Income | -20.30M |
| Net Income | -21.24M |
| EBITDA | -19.67M |
| EBIT | -19.71M |
| Earnings Per Share (EPS) | -$0.58 |
Full Income StatementBalance Sheet
The company has $16.54 million in cash and $672,302 in debt, giving a net cash position of $15.87 million or $0.37 per share.
| Cash & Cash Equivalents | 16.54M |
| Total Debt | 672,302 |
| Net Cash | 15.87M |
| Net Cash Per Share | $0.37 |
| Equity (Book Value) | 14.01M |
| Book Value Per Share | 0.33 |
| Working Capital | 14.34M |
Full Balance SheetCash Flow
| Operating Cash Flow | -19.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 44,689 |
| Net Borrowing | -99,784 |
| Free Cash Flow | -19.37M |
| FCF Per Share | -$0.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |